Meeting
2016 Cancer Survivorship Symposium
Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial.
Authors
Kunal C. Kadakia
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Kunal C. Kadakia , Kelley M Kidwell , Nicholas J. Seewald , Claire Frances Snyder , David A. Flockhart , Janet S Carpenter , Julie L. Otte , Daniel F. Hayes , Anna Maria Storniolo , Vered Stearns , Norah Lynn Henry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Care Coordination and Financial Implications,Communication,Late- and Long-term Effects/Comorbidities,Health Promotion,Psychosocial Issues,Recurrence and Secondary Malignancies
Sub Track
Symptom Management
Clinical Trial Registration Number
NCT00228956
Citation
J Clin Oncol 34, 2016 (suppl 3S; abstr 158)
DOI
10.1200/jco.2016.34.3_suppl.158
Abstract #
158
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer.
First Author: Elizabeth Joyce
Poster
2021 ASCO Annual Meeting
Associations between preexisting nociplastic pain and early discontinuation of aromatase inhibitor therapy in breast cancer.
First Author: Elizabeth Joyce
Poster
2021 ASCO Annual Meeting
Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).
First Author: Fionnuala Crowley
Poster
2020 ASCO Virtual Scientific Program
Genome-wide association study of steady-state letrozole concentration in patients with breast cancer.
First Author: Daniel Louis Hertz